Abstract
Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are naturally arising bioactive lipids. The roles of LPA and S1P in angiogenesis, tumor growth and metastasis have recently emerged. Blood platelets are an important source of LPA and S1P in the organism. However, other types of cells including cancer cells expressing autotaxin and sphingosine kinases have the capacity to produce LPA and S1P, respectively. During the past decade, studies revealed that LPA and S1P interact with a large series of G-protein-coupled receptors, at least seven for LPA (LPA1-5, GPR-87, P2Y5) and five for S1P (S1P1-5). This may account for the wide variety of cell types reacting to LPA and S1P stimulation and for the wide range of cellular functions controlled by these lysophospholipids such as proliferation, survival and motility. Genetic and pharmacological approaches were developed to block the activities of LPA or S1P in the context of cancer progression. This article presents recent findings based on extensive cell culture experiments and preliminary in vivo studies which demonstrate that targeting the lysophospholipid tracks would be extremely beneficial for patients suffering from cancer.
Keywords: Lysophosphatidic acid, sphingosine 1-phosphate, autotaxin, spkingosine kinase, antagonists, receptors, cancer cells
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Volume: 9 Issue: 4
Author(s): Olivier Peyruchaud
Affiliation:
Keywords: Lysophosphatidic acid, sphingosine 1-phosphate, autotaxin, spkingosine kinase, antagonists, receptors, cancer cells
Abstract: Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are naturally arising bioactive lipids. The roles of LPA and S1P in angiogenesis, tumor growth and metastasis have recently emerged. Blood platelets are an important source of LPA and S1P in the organism. However, other types of cells including cancer cells expressing autotaxin and sphingosine kinases have the capacity to produce LPA and S1P, respectively. During the past decade, studies revealed that LPA and S1P interact with a large series of G-protein-coupled receptors, at least seven for LPA (LPA1-5, GPR-87, P2Y5) and five for S1P (S1P1-5). This may account for the wide variety of cell types reacting to LPA and S1P stimulation and for the wide range of cellular functions controlled by these lysophospholipids such as proliferation, survival and motility. Genetic and pharmacological approaches were developed to block the activities of LPA or S1P in the context of cancer progression. This article presents recent findings based on extensive cell culture experiments and preliminary in vivo studies which demonstrate that targeting the lysophospholipid tracks would be extremely beneficial for patients suffering from cancer.
Export Options
About this article
Cite this article as:
Peyruchaud Olivier, Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/1871520610909040381
DOI https://dx.doi.org/10.2174/1871520610909040381 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs)
Current Topics in Medicinal Chemistry Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry MicroRNAs in Renal Cell Carcinoma
MicroRNA Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design The Regulation of miRNAs in Inflammation-Related Carcinogenesis
Current Pharmaceutical Design Advances on PPARγ Research in the Emerging Era of Precision Medicine
Current Drug Targets An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam
Pharmaceutical Nanotechnology A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design Subject Index to Volume 5
Current Drug Targets The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets
Current Drug Targets Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology